A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis

The purpose of this study is to determine whether VIB4920 (formerly MEDI4920) is safe and well tolerated in participants with adult-onset rheumatoid arthritis (RA).

Study with completed results acquired from Horizon in 2024. Originally Viela Bio was the sponsor.

Inclusion Criteria:

• adult-onset rheumatoid arthritis
• swollen and tender joints

Exclusion Criteria:

• venous thromboembolism or arterial thrombosis
• pregnant or breastfeeding
• positive hepatitis B, hepatitis C, and human immunodeficiency virus infection
• active or untreated latent tuberculosis